A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

A 59-year-old woman with a background of HIV living with an uncontrollable movement disorder presented to Eoghan Donlon, MB, BCh BAO, MRCPI, of the Mater Misericordiae University Hospital in Dublin, ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

Chorea in Huntington's disease (HD) is often treated with neuroleptics such as haloperidol, but some patients develop extrapyramidal side effects with these drugs. In many countries, the ...

Benign hereditary chorea (BHC) is a rare, autosomal dominant neurological disorder characterised by early-onset, non-progressive chorea. Mutations in the NKX2-1 gene, which encodes the thyroid ...

THIS report describes the clinical, laboratory and genetic investigations of a large Negro family, many of whose members exhibit choreiform movements of early onset and nonprogressive nature. As far ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by ...